Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?
In a past Free Thinking paper,
we looked at the opportunity and challenges for biosimilar mAbs entering the
rheumatoid arthritis market. A few years later and according to our Therapy
Watch patient record data, uptake of biosimilars remains relatively muted, with
marked inconsistencies across the major European markets. With Enbrel
biosimilar Benepali about to launch across EU, we ask what’s next for RA?
Register to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes. Research Partnership
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space. Research Partnership
Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers Research Partnership